Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC's IPO & More
02:20pm, Friday, 24'th Apr 2020
COVID-19’s spread has clamped down on a lot of economic activity, including the work of developing and testing new medicines. But the FDA isn’t showing
Bank of America Corp DE Has $1.38 Million Stock Holdings in Esperion Therapeutics Inc (NASDAQ:ESPR)
08:42am, Wednesday, 22'nd Apr 2020
Bank of America Corp DE lifted its stake in shares of Esperion Therapeutics Inc (NASDAQ:ESPR) by 3.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund o
Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Reaffirmed by Needham & Company LLC
06:30am, Wednesday, 22'nd Apr 2020
Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating restated by research analysts at Needham & Company LLC in a research note issued to investors on Monday, TipRanks reports. They c
Broker Revenue Forecasts For Esperion Therapeutics, Inc. (NASDAQ:ESPR) Are Surging Higher
11:04am, Tuesday, 21'st Apr 2020
Shareholders in Esperion Therapeutics, Inc. (NASDAQ:ESPR) may be thrilled to learn that the analysts have just...
Industry Analysts Just Upgraded Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Forecasts By 15%
11:01am, Tuesday, 21'st Apr 2020
Esperion Therapeutics, Inc. (NASDAQ:ESPR) shareholders will have a reason to smile today, with the analysts making...
Esperion Therapeutics (NASDAQ:ESPR) Given Buy Rating at Stifel Nicolaus
07:14am, Tuesday, 21'st Apr 2020
Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reissued by research analysts at Stifel Nicolaus in a research report issued to clients and investors on Monday, TipRanks reports
Talos Energy, Inc. (TALO): Were Hedge Funds Right About This Stock?
02:33am, Tuesday, 21'st Apr 2020
"I have been following Dr. Inan Dogan since this outbreak, and he is a phenomenally intelligent researcher. One month ago, Dr. Dogan's prediction that the total U.S. death toll would be 20,000+ by A
Needham Reiterates a Buy Rating on Esperion (ESPR)
07:53pm, Monday, 20'th Apr 2020
Needham analyst Chad Messer reiterated a Buy rating on Esperion (ESPR) today and set a price target of $158.00. The company's shares closed last Monday at
Needham Reiterates a Buy Rating on Esperion (ESPR)
07:53pm, Monday, 20'th Apr 2020
Needham analyst Chad Messer reiterated a Buy rating on Esperion (ESPR – Research Report) today and set a price target
JMP Reiterates $191 Price Target On Esperion After Japan Partnership
05:41pm, Monday, 20'th Apr 2020
JMP Securities analyst Jason Butler reiterates an
Esperion (ESPR) Received its Third Buy in a Row
04:33pm, Monday, 20'th Apr 2020
After Needham and Merrill Lynch gave Esperion (NASDAQ: ESPR) a Buy rating last month, the company received another Buy, this time from Stifel Nicolaus.
Esperion (ESPR) Received its Third Buy in a Row
04:33pm, Monday, 20'th Apr 2020
After Needham and Merrill Lynch gave Esperion (NASDAQ: ESPR) a Buy rating last month, the company received another Buy, this
JMP reiterates $191 price target on Esperion after Japan partnership ESPR
03:35pm, Monday, 20'th Apr 2020
JMP reiterates $191 price target on Esperion after Japan partnership JMP Securities ESPR
Esperion (ESPR) Receives a Hold from Northland Securities
12:23pm, Monday, 20'th Apr 2020
Northland Securities analyst Carl Byrnes maintained a Hold rating on Esperion (ESPR) today and set a price target of $42.00. The company's shares closed
Esperion (ESPR) Receives a Hold from Northland Securities
12:23pm, Monday, 20'th Apr 2020
Northland Securities analyst Carl Byrnes maintained a Hold rating on Esperion (ESPR – Research Report) today and set a price
